Beam Therapeutics (BEAM) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
10 Sep, 2026Vision and technology
Aims to provide lifelong, one-time curative therapies for rare and common diseases using base editing technology, offering predictable and durable gene correction with less genotoxicity than traditional methods.
Platform enables rapidly programmable precision medicines adaptable to new targets, with reusable delivery technology and scalable internal manufacturing.
Financial strength and growth
Holds $1.2 billion in cash as of June 30, 2026, plus potential $200 million from a credit facility, expected to fund operations into mid-2029.
Focused investment strategy supports efficient commercial build and pipeline expansion, targeting significant addressable markets.
Liver-targeted genetic disease franchise
Advancing a portfolio of in vivo programs for diseases like AATD, GSDIa, and PKU, leveraging industry-leading LNP capabilities.
BEAM-302 for AATD shows durable AAT increases above protective thresholds, with 84% reduction in mutant Z-AAT and favorable safety profile; pivotal trial dosing initiated in July 2026.
BEAM-304 for PKU and BEAM-301 for GSDIa designed for early clinical proof of concept, with preclinical data supporting rapid normalization of disease markers.
Latest events from Beam Therapeutics
- BEAM-302 advances toward pivotal follow-up as risto-cel targets a December 2026 BLA.BEAM
Jefferies Global Healthcare Conference - Positive sickle cell results, advancing AAT enrollment and striking early GSD1a data drive the pipeline.BEAM
UBS Global Biopharma Conference 2026 - Risto-cel nears BLA filing as in vivo editing programs advance.BEAM
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical programs advanced as Q3 losses widened and runway extended into mid-2029, subject to facility conditions.BEAM
Q3 2026 - Two of three patients at 40 mg reached 15-hour fasting and stopped starch supplementation.BEAM
Study result - Gene editing pipeline advances with durable results, strong safety, and first-mover advantage.BEAM
12th Annual Cantor Fitzgerald Global Healthcare Conference - BEAM-302 gene editing achieved sustained, functional AAT restoration and was well tolerated.BEAM
European Respiratory Society Congress presentation - Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability.BEAM
Citigroup’s Biopharma Back to School Summit 2026 - Durable AAT restoration and >80% Z-AAT reduction advance toward pivotal approval.BEAM
Status update